Targeting the latest hallmark of cancer: Another attempt at 'magic bullet drugs targeting cancers metabolic phenotype

Future Oncology

Volumn 8, Issue 10, 2012, Pages 1315-1330

  Cuperlovic Culf, M ^a   Culf, A S ^b   Touaibia, M ^c   Lefort, N ^b  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b ATLANTIC CANCER RESEARCH INSTITUTE   (Canada)

^c UNIVERSITÉ DE MONCTON   (Canada)

Author keywords

cancer metabolic phenotype; cancer research; drug discovery; metabolomics; targeted therapies

Indexed keywords

6 PHOSPHOFRUCTO 2 KINASE INHIBITOR; 8 [2,4 DICHLOROPHENYL] 2 HYDROXYOCTYL) 2 HYDROXYSUCCINIC ACID; ADENOSINE TRIPHOSPHATASE INHIBITOR; ADENOSINE TRIPHOSPHATE CITRATE LYASE INHIBITOR; ANTINEOPLASTIC AGENT; ARC 117977; ATORVASTATIN; AZD 7545; CD 017 0191; CP 640186; DEOXYGLUCOSE; DICHLOROACETIC ACID; FATTY ACID SYNTHASE INHIBITOR; FLAVONOID; FLUINDOSTATIN; HISTONE DEACETYLASE INHIBITOR; HYDROXYCITRIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTATE DEHYDROGENASE INHIBITOR; LONIDAMINE; METFORMIN; MEVINOLIN; MITOCAN; NARINGENIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHLORETIN; PHOSPHOTRANSFERASE INHIBITOR; PITAVASTATIN; PRAVASTATIN; QUERCETIN; ROSUVASTATIN; SB 201076; SB201076; SB204990; SILIBININ; SIMVASTATIN; TEIB 00422; TETRAHYDROLIPSTATIN; TH 070; TLN 232; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BRAIN CANCER; BREAST CANCER; CANCER GROWTH; CANCER THERAPY; CELL DIVISION; CELL METABOLISM; CELL PROLIFERATION; COLORECTAL CANCER; DRUG TARGETING; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; GENITAL TRACT CANCER; GLIOBLASTOMA; GLIOMA; GLUCOSE INTAKE; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; KIDNEY CARCINOMA; LIVER CANCER; LUNG CANCER; MITOCHONDRION; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; THYROID CANCER; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT; UPREGULATION;

ANTIBODIES, MONOCLONAL; ENZYME INHIBITORS; FATTY ACIDS; GLYCOLYSIS; HUMANS; LIPOGENESIS; METABOLIC NETWORKS AND PATHWAYS; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84868542684     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.121     Document Type: Review

References (124)

1. Cairns R, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat. Rev. Cancer, 11, 85-95 (2011
2. Kroemer G, Pouyssegur J. Tumor cell metabolism: Cancer's Achilles' heel. Cancer Cell 13, 472-482 (2008 (Pubitemid 351766797)
3. Allen M, Jones JL. Jekyll and Hyde: The role of the microenvironment on the progression of cancer. J. Pathol. 223, 162-176 (2011
4. Tennant D, Duran RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer 10, 267-277 (2010
5. Purcell WT, Ettinger DS. Novel antifolate drugs. Curr. Oncol. Rep. 5, 114-125 (2003 (Pubitemid 38898774)
6. Ramos-Montoya A, Lee WN, Bassilian S et al. Pentose phosphate cycle oxidative and nonoxidative balance: A new vulnerable target for overcoming drug resistance in cancer. Int. J. Cancer 119, 2733-2741 (2006 (Pubitemid 44846223)
7. Vizan P, Alcarraz-Vizan A, Diaz-Moralli S, Solovjeva O, Frederiks WM, Cascante M. Modulation of pentose phosphate pathway during cell cycle progression in human colon adenocarcinoma cell line HT29. Int. J. Cancer 124, 2789-2796 (2009
8. Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveaux P. Anticancer targets in the glycolytic metabolism of tumors: A comprehensive review. Front. Pharm. 2, 1-18 (2011
9. Cao X, Fang L, Gibbs S et al. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemo Pharm. 59, 495-505 (2007 (Pubitemid 46122328)
10. Flaig TW, Glodé M, Gustafson D et al. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate 70(8), 848-855 (2010
11. Zhang W, Liu Y, Chen X, Bergmeier SC. Novel inhibitors of basal glucose transport as potential anticancer agents. Bioorg. Med. Chem. Lett. 20, 2191-2194 (2010
12. Chan DA, Sutphin PD, Nguyen P et al. Targeting GLUT1 and the warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci. Transl. Med. 3, 94ra70 (2011
13. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 25, 4633-4646 (2006 (Pubitemid 44187614)
14. Chen W, Guéron M. The inhibition of bovine heart hexokinase by 2-deoxy-dglucose- 6-phosphate: Characterization by 31P NMR and metabolic implications. Biochimie 74, 867-873 (1992
15. Landau BR, Laszlo J, Stengle J, Burk D. Certain metabolic and pharmacologic effects in cancer patients given infusions of 2-deoxy-D-glucose. J. Natl Cancer Inst. 21, 485-494 (1958
16. Atsumi T, Chesney J, Metz C et al. High expression of inducible 6-phosphofructo-2- kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res. 62, 5881-5887 (2002 (Pubitemid 35204749)
17. Clem B, Telang S, Clem A et al. Smallmolecule inhibition of 6-phosphofructo-2- kinase activity suppresses glycolytic flux and tumor growth. Mol. Cancer Ther. 7, 110-120 (2008
18. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin. Cancer Biol. 15, 300-308 (2005 (Pubitemid 41058775)
19. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324, 1029-1033 (2009
20. Vander Heiden MG, Christofk HR, Schuman E et al. Identification of small molecule inhibitors of pyruvate kinase M2. Biochem. Pharmacol. 79, 1118-1124 (2010
21. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 3, 177-185 (2006
22. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively down regulating mitochondrial oxygen consumption. Cell Metab. 3, 187-197 (2006
23. Whitehouse S, Cooper RH, Randle PJ. Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids. Biochem. J. 141, 761-774 (1974
24. Bonnet S, Archer SL, Allalunis-Turner J et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11, 37-51 (2007 (Pubitemid 46054520)
25. Michelakis ED, Sutendra G, Dromparis P et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci. Trans. Med. 2, 31ra34 (2010
26. Aicher TD, Damon RE, Koletar J et al. Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK). Bioorg. Med. Chem. Lett. 9, 2223-2228 (1999 (Pubitemid 29371940)
27. Aicher TD, Anderson RC, Gao J et al. Secondary amides of (R)-3,3,3-trifluoro-2- hydroxy-2-methylpropionic acid as inhibitors of pyruvate dehydrogenase kinase. J. Med. Chem. 43, 236-249 (2000
28. Bebernitz GR, Aicher TD, Stanton JL et al. Anilides of (R)-trifluoro-2-hydroxy-2- methylpropionic acid as nhibitors of pyruvate dehydrogenase kinase. J. Med. Chem. 43, 2248-2257 (2000 (Pubitemid 30354549)
29. Sonveau P, Vegran F, Schoroeder T et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest. 118, 3930-3942 (2008
30. Le A, Cooper CR, Gouw AM et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl Acad. Sci. USA 107, 2037-2042 (2010
31. Granchi C, Bertini S, Macchia M, Minutolo F. Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials. Cur. Med. Chem. 17, 672-697 (2010
32. Granchi C, Roy S, De Simone A et al. N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation. Eur. J. Med. Chem. 46, 5398-5407 (2011
33. Kroemer G. Mitochondria in cancer. Oncogene 25, 4630-4632 (2011 (Pubitemid 44187613)
34. Warburg O. On the origin of cancer cells. Science 123, 309-314 (1956
35. Vazquez A, Oltvai ZN. Molecular crowding defines a common origin for the Warburg effect in proliferating cells and the lactate threshold in muscle physiology. PLoS ONE 6, e19538 (2011
36. Bhalla K, Hwang BJ, Dewi RE et al. PGC1a promotes tumor growth by inducing gene expression programs supporting lipogenesis. Cancer Res. 71, 6888-6898 (2011
37. D'Errico I, Salvatore L, Murzilli S et al. Peroxisome proliferator-activated receptor-g coactivator 1-a (PGC1a) is a metabolic regulator of intestinal epithelial cell fate. Proc. Natl Acad. Sci. USA 108, 6603-6608 (2011
38. Wang X, Moraes CT. Increases in mitochondrial biogenesis impair carcinogenesis at multiple levels. Mol. Oncol. 5, 399-409 (2011
39. Guan KL, Xiong Y. Regulation of intermediary metabolism by protein acetylation. Trends Biochem. Sci. 36,108-116 (2011
40. Amoêdo ND, Rodrigues MF, Pezzuto P et al. Energy metabolism in H460 lung cancer cells: Effects of histone deacetylase inhibitors. PLoS ONE 6, e22264 (2011
41. Hirschey MD, Shimazu T, Jing E et al. SIRT3 deficiency and mitochondrial protein hyperacetylation ccelerate the development of the metabolic syndrome. Mol. Cell 44, 177-190 (2011
42. Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med. Oncol. 29(2), 1314-1327 (2011
43. Biasutto L, Dong LF, Zoratti M, Neuzil J. Mitochondrially targeted anti-cancer agents. Mitochondrion 10, 670-681 (2010
44. Dong LF, Freeman R, Liu J et al. Suppression of tumor growth in vivo by the mitocan a-tocopheryl succinate requires respiratory complex II. Clin. Cancer Res. 15, 1593-1600 (2009
45. Raj L, Ide T, Gurkar AU et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475, 231-234 (2011
46. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metfomin in non-insulin-dependent diabetes mellitus. New Eng. J. Med. 333, 550-554 (1995
47. Hundal HS, Ramlal T, Reyes R, Leiter LA, Klip A. Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells. Endocrinology 131, 1165-1173 (1992
48. Owen M, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex I of the mitochondrial respiratory chain. Biochem. J. 348, 607-614 (2000 (Pubitemid 30410251)
49. Shaw RJ, Kosmatka M, Bardessey N et al. The tumor supressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl Acad. Sci. USA 101, 3329-3335 (2004 (Pubitemid 38338195)
50. Pierotti MA, Berrino F, Gariboldi M et al. Targeting metabolism for cancer treatment and prevention: Metformin, an old drug with multi-faceted effects. Oncogene doi:10.1038/ onc.2012.181 (2012) (Epub ahead of print
51. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. Br. Med. J. 330, 1304-1305 (2005 (Pubitemid 40813563)
52. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29, 254-258 (2006 (Pubitemid 44106500)
53. Blandino G, Valerio M, Cioce M et al. Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. Nat. Commun. 3, 865 (2012
54. Wu B, Li S, Sheng L et al. Metformin inhibits the development and metastasis of ovarian cancer. Oncol. Reprod. 28, 903-908 (2012
55. Martin M, Marais R. Metformin: A diabetes drug for cancer, or a cancer drug for diabetics? J. Clin. Oncol. 30(21), 2698-2700 (2012
56. Zaugg K, Yao Y, Reilly PT et al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev. 25, 1041-1051 (2011
57. Zhou W, Tu Y, Simpson PJ, Kuhajda FP. Malonyl-CoA decarboxylase inhibition is selectively cytotoxic to human breast cancer cells. Oncogene 28, 2979-2987 (2009
58. Nieman KM, Kenny HA, Penicka CV et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 17, 1498-1503 (2011
59. Das SK, Eder S, Schauer S et al. Adipose triglyceride lipase contributes to cancerassociated cachexia. Science 333(6039), 233-238 (2011
60. Swinnen JV, Van Veldhoven PP, Timmermans L et al. Fatty acid synthase drives the synthesis of phospholipids partitioning into detergentresistant membrane microdomains. Biochem. Biophys. Res. Commun. 302, 898-903 (2003 (Pubitemid 36294061)
61. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 7, 763-777 (2007 (Pubitemid 47469806)
62. Mashima T, Seimiya H, Tsuruo T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br. J. Cancer 100, 1369-1372 (2009
63. Migita T, Narita T, Nomura K et al. ATP citrate lyase: Activation and therapeutic implications in non-small cell lung cancer. Cancer Res. 68, 8547-8554 (2008
64. Hatzivassiliou G, Zhao F, Bauer DE et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8, 311-321 (2005 (Pubitemid 41443416)
65. Beckner ME, Fellows-Mayle W, Zhang Z et al. Identification of ATP citrate lyase as a positive regulator of glycolytic function in glioblastomas. Int. J. Cancer 126, 2282-2295 (2010
66. Pearce NJ, Yates JW, Berkhout TA et al. The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem. J. 334, 113-119 (1998
67. López-Lázaro M. The Warburg effect: Why and how do cancer cells activate glycolysis in the presence of oxygen? Anticancer Agents Med. Chem. 8, 305-312 (2008 (Pubitemid 351761435)
68. Pappenberger G, Benz J, Gsell B et al. Structure of the human fatty acid synthase KS-MAT didomain as a framework for inhibitor design. J. Mol. Biol. 397, 508-519 (2010
69. De Schrijver E, Brusselmans K, Heyns W, Verhoeven G, Swinnen JV. RNA interferencemediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res. 63, 3799-3804 (2003 (Pubitemid 36793069)
70. Kridel SJ, Lowther WT, Pemble CW 4th. Fatty acid synthase inhibitors: new directions for oncology. Expert Opin Invest. Drugs 16, 1817-1829 (2007
71. Price AC, Choi KH, Heath RJ, Li Z, White SW, Rock CO. Inhibition of b-ketoacyl-acyl carrier protein synthases by thiolactomycin and cerulenin. Structure and mechanism. J. Biol. Chem. 276, 6551-6559 (2001
72. Moche M, Schneider G, Edwards P, Dehesh K, Lindqvist Y. Structure of the complex between the antibiotic cerulenin and its target, b-ketoacyl-acyl carrier protein synthase J. Biol. Chem. 274, 6031-6034 (1999 (Pubitemid 29111003)
73. Wang X, Tian W. Green tea epigallocatechin gallate: A natural inhibitor of fatty acid synthase. Biochem. Biophys. Res. Commun. 288, 1200-1206 (2001 (Pubitemid 33131728)
74. Menendez JA, Colomer R, Lupu R. Inhibition of fatty acide synthase-dependent neoplastic lipogenesis as the mechanism of g-linolenic acid-induced toxicity to tumor cells: An extension to Nwankwo's hypothesis. Med. Hypothesis 64, 337-341 (2005 (Pubitemid 40028282)
75. Vázquez MJ, Leavens W, Liu R et al. Discovery of GSK837149A, an inhibitor of human fatty acid synthase targeting the b-ketoacyl reductase reaction. FEBS J. 275, 1556-1567 (2008 (Pubitemid 351388801)
76. Zhan Y, Ginanni N, Tota MR et al. Control of cell growth and survival by enzymes of the fatty acid synthesis pathway in HCT-116 colon cancer cells. Clin. Cancer Res. 14, 5735-5742 (2008
77. Brusselmans K, De Schrijver E, Verhoeven G, Swinnen JV. RNA interference-mediated silencing of the acetyl coA carboxylase-a gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res. 65, 6719-6725 (2005 (Pubitemid 41060709)
78. Waldrop GL, Stephens JM. Targeting acetyl coA carboxylase for anti-obesity therapy. Curr. Med. Chem. Immunol. Endocr. Metabol. Agents 3, 229-234 (2003
79. Thupari JN, Pinn ML, Kuhajda FP. Fatty acid synthase inhibition in human breast cancer cells leads to malonyl coA induced inhibition of fatty acid oxidation and cytotoxicity. Biochem. Biophys. Res. Commun. 285, 217-223 (2001 (Pubitemid 32918056)
80. Wang C, Xu C, Sun M, Luo D, Liao DF, Cao D. Acetyl coA carboxylase-a inhibitor TOFA induces human cancer cell apoptosis. Biochem. Biophys. Res. Commun. 385, 302-306 (2009
81. Sugimoto Y, Naniwa Y, Nakamura T et al. A novel acetyl-CoA carboxylase inhibitor reduces de novo fatty acid synthesis in HepG2 cells and rat primary hepatocytes. Archiv. Biochem. Biophys. 468, 44-48 (2007 (Pubitemid 350087850)
82. Beckers A, Organe S, Timmermans L et al. Chemical inhibition of acetyl coA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res. 67, 8180-8187 (2007 (Pubitemid 47395154)
83. Harwood HJ Jr, Petras SF, Shelly LD et al. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals. J. Biol. Chem. 278, 37099-37111 (2003
84. Zhang H, Tweel B, Li J, Tong L. Crystal Structure of the carboxyltransferase domain of acetyl-coenzyme a carboxylase in complex with CP-640186. Structure 12, 1683-1692 (2004
85. Marjanovic J, Chalupska D, Patenode C et al. Recombinant yeast screen for new inhibitors of human acetyl-CoA carboxylase 2 identifies potential drugs to treat obesity. Proc. Natl Acad. Sci. USA 107, 9093-9098 (2010
86. Gu YG, Weitzberg M, Clark RF et al. Synthesis and structure - activity relationships of N-{3-[2-(4-Alkoxyphenoxy) thiazol-5-yl]-1- methylprop-2-ynyl} carboxy derivatives as selective acetyl-CoA carboxylase 2 inhibitors. J. Med. Chem. 49, 3770-3773 (2006 (Pubitemid 43967876)
87. Vaklavas C, Chatzizisis YS, Tsimberidou AM. Common cardiovascular medications in cancer therapeutics. Pharmcol. Ther. 130, 177-190 (2011
88. Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: A comprehensive review. Expert Opin Drug Saf. 9, 603-621 (2010
89. Mondul AM, Han M, Humphreys EB, Meinhold CL, Walsh PC, Platz EA. Association of statin use with pathological tumor characteristics and prostate cancer recurrence after surgery. J. Urol. 185, 1268-1273 (2011
90. Khurana V, Bejjanki HR, Caldito G, Owens MW. Statins reduce the risk of lung cancer in humans: A large case-control study of US veterans. Chest 131, 1282-1288 (2007 (Pubitemid 46762329)
91. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk. JAMA 295, 74-80 (2006
92. Jacobs EJ, Newton CC, Thun MJ, Gapstur SM. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res. 71, 1763-1771 (2011
93. Clendening JW, Pandyra A, Boutros PC et al. Dysregulation of the mevalonate pathway promotes transformation. Proc. Natl Acad. Sci. USA 107, 15051-15056 (2010
94. Halestrap AP. The monocarboxylate transporter family-Structure and functional characterization. IUBMB Life 64, 1-9 (2012
95. Zheng XT, Yang HB, Li CM. Optical detection of single cell lactate release for cancer metabolic analysis. Anal. Chem. 82, 5082-5087 (2010
96. Semenza GL. Tumor metabolism: Cancer cells give and take lactate. J. Clin. Invest. 118, 3835-3837 (2008
97. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J. Nucl. Med. 49, S24-S42 (2008
98. Robey IF, Baggett BK, Kirkpatrick D et al. Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res. 69, 2260-2268 (2009
99. Végran F, Boidot R, Michiels C, Sonveaux P, Feron O. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-kB/IL-8 pathway that drives tumor angiogenesis. Cancer Res. 71, 2550-2560 (2011
100. Shim CK, Cheon EP, Kang KW, Seo KS, Han HK. Inhibition effect of flavonoids on monocarboxylate transporter 1 (MCT1) in Caco-2 cells. J. Pharm. Pharmacol. 59, 1515-1519 (2007
101. Wang X, Levi AJ, Halestrap AP. Substrate and inhibitor specificities of the monocarboxylate transporters of single rat heart cells. Am. J. Physiol. Heart Circ. Physiol. 270, H476-H484 (1996
102. Melena J, Safa R, Graham M, Casson RJ, Osborne NN. The monocarboxylate transport inhibitor, a-cyano-4-hydroxycinnamate, has no effect on retinal ischemia. Brain Res. 989, 128-134 (2003 (Pubitemid 37281410)
103. Murray CM, Hutchinson R, Bantick JR et al. Monocarboxylate transporter MCT1 is a target for immunosuppression. Nat. Chem. Biol. 1, 371-376 (2005
104. Bueno V, Binet I, Steger U et al. The specific monocarboxylate transporter (MCT1) inhibitor, AR C117977, a novel immunosuppressant, prolongs allograft survival in the mouse. Transplantation 84(9), 1204-1207 (2007 (Pubitemid 350125365)
105. Ovens MJ, Davies AJ, Wilson MC, Murray CM, Halestrap AP. AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10. Biochem. J. 425(3), 523-530 (2010
106. Izumi H, Takahashi M, Uramoto H et al. Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells. Cancer Sci. 102, 1007-1013 (2011
107. Supuran CT. Carbonic anhydrase inhibitors. Bioorg. Med. Chem. Lett. 20, 3467-3474 (2010
108. Poulsen S. Carbonic anhydrase inhibition as a cancer therapy: A review of patent literature, 2007-2009. Expert Opin Ther. Pat. 20(6), 795-806 (2010
109. Alterio V, Hilvo M, Di Fiore A et al. Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX. Proc. Natl Acad. Sci. USA 106, 16233- 16238 (2009
110. Buller F, Steiner M, Frey K et al. Selection of carbonic anhydrase ix inhibitors from one million DNA-encoded compounds. ACS Chem. Biol. 6, 336-344 (2011
111. Pacchiano F, Carta F, McDonald PC et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J. Med. Chem. 54, 1896-1902 (2011
112. Dittrich C, Zandvliet AS, Gneist M, Huitema AD, King AA, Wanders J. A Phase I and pharmacokinetic study of indisulam in combination with carboplatin. Br. J. Cancer 96, 559-566 (2007
113. Talbot DC, von Pawel J, Cattell E et al. A randomized Phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 13, 1816-1822 (2007 (Pubitemid 46952951)
114. Samid D, Yeh A, Prasanna P. Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate. Blood 80, 1576-1481 (1992
115. Gao P, Tchernyshyov I, Chang TC et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458, 762-765 (2009
116. Seltzer MJ, Bennett BD, Joshi AD et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 70, 8981-8987 (2010
117. Wang JB, Erickson JW, Fuji R et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18, 207-219 (2010
118. Rosenfeld H, Roberts J. Enhancement of antitumour activity of glutamine antagonists 6-diazo-5-oxo-l-norleucine and acivicin in cell culture by glutamineasparginase. Cancer Res. 41, 1324-1328 (1981 (Pubitemid 11146759)
119. Masetti R, Pession A. First-line treatment of acute lymphoblastic leukemia with peg asparaginase. Biologics 3, 359-368 (2009
120. Haskell CM, Canellos GP. L-asparaginase resistance in human leukemia-asparagine synthetase. Biochem. Pharmacol. 18, 2578-2580 (1969
121. Haskell CM, Canellos GP, Leventhal BG et al. L-asparaginase: Therapeutic and toxic effects in patients with neoplastic disease. N. Engl. J. Med. 281, 1028-1034 (1969
122. Wheatley DN. Controlling cancer by restricting arginine availability - argininecatabolizing enzymes as anticancer agents. Anticancer Drugs 15, 825-833 (2004 (Pubitemid 39482922)
123. Ni Y, Schwaneberg U, Sun ZH. Arginine deiminase, a potential anti-tumor drug. Cancer Lett. 261, 1-11 (2008
124. Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M. The KEGG resource for deciphering the genome. Nucleic Acids Res. 32(Database issue), D277-D280 (2004 (Pubitemid 38081656)